Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders

10 Jun 2026
www.prnewswire.com
Oligonucleotide
Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world.
Servier strengthens its commitment to rare neurological diseases through collaboration with n-Lorem Foundation on rare genetic neurodevelopmental disorders.
This partnership will enhance the number of patients n-Lorem can treat.
SURESNES, France and SAN DIEGO, June 10, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical company governed by a foundation, and n-Lorem Foundation, a non-profit organization established to charitably provide experimental medicines to treat nano-rare patients with high unmet needs, are entering into a multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches to address rare and devastating neurodevelopmental disorders.
Continue Reading
View PDF
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
As part of the agreement, n-Lorem research teams will leverage their pioneering ASO technology platform to engineer preclinical candidates, which Servier will advance into clinical development. Antisense oligonucleotides (ASOs) are designed to target disease-causing RNA and may enable highly personalized approaches to treating genetic disorders. This approach opens a new frontier in medicine— addressing the root cause of the disease and offering the potential to tackle previously intractable neurological conditions.
Servier this collaboration, Servier and n-Lorem aim to extend the reach of precision genetic medicine to patients living with rare neurological disorders, many of whom currently have no approved treatment options. In addition, the partnership represents another step toward achieving Servier's 2030 ambition of developing innovative treatments for people living with rare neurological diseases, where significant unmet medical need remains, including, refractory epilepsy, genetically-driven autism spectrum disorders, leukodystrophies, peripheral neuropathies, movement disorders and neuromuscular diseases.
"We are proud to partner wn-Loremorem, sharing the same commitment to advancing personalized ASOs and bringing meaningful therapies to people liviServier rare genetic neurological disorders who have few, if any, treatment options available today, saidgenetic disorders
Nitza Thomasson, Global HeadServier Neurn-Loremt Servier. "This partnership builds on a shared belief in open, multidisciplinary coneurological disordersn strong science to accelerate research and deliver new therapies for patients. By combining n-Lorem's pioneering expertise in antiServierechnology with Servier's development capabilities, we aim at accelerating nerare neurological diseaseswho have been waiting for far too long."refractory epilepsyautism spectrum disordersleukodystrophiesperipheral neuropathiesmovement disordersneuromuscular diseases
"We welcome Servier to our growing list of supporters and partners and look forward to contributing to Servier's commitment to patients with rare neurological genetic neurological disorders technology. This is truly a win, win for patients with rare diseases," said
Stanley T. Crooke, Founder, Chairman and CEO of nServiern-LoremServier
[email protected]
Media Contact Servier foundation
Amy Williford, Ph.D.
Vice President, Foundation Development and External Relations
[email protected]
SOURCE Servier
21%
more press release views with
Request a Demo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!